31.1.2024 16:04:10 CET | Aqua Bio Technology ASA | Additional regulated
information required to be disclosed under the laws of a member state
Reference is made to the stock exchange announcements by Aqua Bio Technology ASA
("ABTEC" or the "Company") on 29 and 30 January 2024 regarding the Private
Placement and the contemplated Subsequent Offering as described therein.
The Subsequent Offering consists of an offering of up to 1,000,000 new shares in
the Company (the "Offer Shares") directed towards the shareholders of the
Company as of 30 January 2024 (as registered in the VPS on 1 February 2024) (the
"Record Date"), except; (i) shareholders that subscribed for shares in the
Private Placement, and (ii) shareholders who are resident in a jurisdiction
where such offering would be unlawful, or would require any prospectus filing,
registration or similar action (the "Eligible Shareholders").
In addition, the following types of investors shall have a secondary right to
subscribe for the Offer Shares; (i) ABTEC shareholders and investors that
participated in the Private Placement, (ii), and (iii) other subscribers without
Subscription Rights (as defined below), subject to a minimum allocation of at
least NOK 5,000 (jointly, the "Secondary Subscribers").
The subscription period in the Subsequent Offering commences on 5 February 2024
at 09:00 hours (CET) and will end on 9 February 2024 at 16:30 hours (CET) (the "
Subscription Period"). The subscription price per Offer Share is NOK 5.00 (the "
Subscription Price"), which is equal to the subscription price in the Private
Placement. If fully subscribed, the Subsequent Offering will raise gross
proceeds of NOK 5,000,000.
In the Subsequent Offering, Eligible Shareholders, will be granted
non-transferable subscription rights (the "Subscription Rights") that, subject
to applicable law, provide preferential rights to subscribe for and be allocated
Offer Shares at the Subscription Price.
The Eligible Shareholders will be granted a certain number of Subscription
Rights for each existing share registered as held by such Eligible Shareholder
as of the Record Date, rounded down to the nearest whole number of Subscription
Rights. Secondary Subscribers will not be granted Subscription Rights. Each
whole Subscription Right will provide a preferential right to subscribe for, and
be allocated, one Offer Share at the Subscription Price. Over-subscription will
be permitted. Other than subscriptions from Secondary Subscribers, subscription
without Subscription Rights will not be permitted.
The Subscription Rights must be used to subscribe for Offer Shares before the
expiry of the Subscription Period on 9 February 2024 at 16.30 hours (CET).
Subscription Rights that are not used to subscribe for Offer Shares before 16.30
hours (CET) on 9 February 2024 will have no value and will lapse without
compensation to the holder.
Completion of the Subsequent Offering is subject to, inter alia, approval from
the Company's Board of Directors. The Offer Shares allocated in the Subsequent
Offering will be resolved issued by the Board of Directors pursuant to an
authorization to increase the share capital.
An invitation letter (the "Invitation Letter") will be prepared in connection
with the Subsequent Offering, which sets out the terms and conditions for the
Subsequent Offering and includes a description of certain risk factors
pertaining to the Company, its shares, and the Subsequent Offering.
The Invitation Letter and the specific number of subscription rights for each
Eligible Shareholder will be published prior to the start of the subscription
period, and will also be made available at websites of Norne Securities AS,
www.norne.no/ABTEC - http://www.norne.no/ABTEC.
Norne Securities AS is acting as Settlement Agent for the Subsequent Offering.
Advokatfirmaet CLP DA is acting as legal counsel to the Company in the
Subsequent Offering.
* * *
For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941
32 288.
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. ABT's focus on commercialization and development of natural
ingredients and natural skin care products has been, and will continue to be, an
important part of the Company's strategy going forward. Aqua Bio Technology is
listed on the Euronext Expand market of the Oslo Stock Exchange.
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
DISCLOSURE REGULATION
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
CONTACTS
* Håvard Lindstrøm, 004794132288, hl@aquabiotech.no
ABOUT AQUA BIO TECHNOLOGY ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/2882/4013/Download%20announcement
%20as%20PDF.pdf
Recent Comments